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Sarcoidosis is an inflammatory granulomatous disease with unknown etiology driven by cytokines and chemokines. There is
limited information regarding the regulation of cytokine/chemokine-receptor network in bronchoalveolar lavage (BAL) cells in
pulmonary sarcoidosis, suggesting contribution of miRNAs and transcription factors. We therefore investigated gene expression
of 25 inflammation-related miRNAs, 27 cytokines/chemokines/receptors, and aTh1-transcription factor T-bet in unseparated BAL
cells obtained from 48 sarcoidosis patients and 14 control subjects using quantitative RT-PCR. We then examined both miRNA-
mRNA expressions to enrich relevant relationships. This first study on miRNAs in sarcoid BAL cells detected deregulation ofmiR-
146a,miR-150,miR-202,miR-204, andmiR-222 expression comparing to controls. Subanalysis revealed higher number ofmiR-155,
let-7c transcripts in progressing (𝑛 = 20) comparing to regressing (𝑛 = 28) disease as assessed by 2-year follow-up. Correlation
network analysis revealed relationships between microRNAs, transcription factor T-bet, and deregulated cytokine/chemokine-
receptor network in sarcoid BAL cells. Furthermore,T-bet showedmore pronounced regulatory capability to sarcoidosis-associated
cytokines/chemokines/receptors than miRNAs, which may function rather as “fine-tuners” of cytokine/chemokine expression.
Our correlation network study implies contribution of both microRNAs and Th1-transcription factor T-bet to the regulation of
cytokine/chemokine-receptor network in BAL cells in sarcoidosis. Functional studies are needed to confirm biological relevance
of the obtained relationships.
1. Introduction
Pulmonary sarcoidosis is an inflammatory disorder of un-
known etiology characterized by the accumulation of acti-
vated Th1/Th17 lymphocytes and macrophages in the alve-
oli and subsequent granuloma formation [1–3]. The key
role in the pathogenesis of sarcoidosis is played by proin-
flammatory cytokines and chemokines, molecules crucially
involved in the activation of immune and inflammatory
cells and their trafficking to the site of disease [4]. How-
ever, there is still limited information about the regulation
of the cytokine/chemokine-receptor network in pulmonary
sarcoidosis and its phenotypes.
There is a growing body of evidence that the regula-
tion of inflammatory response is a very complex process
involving coordinated participation of multiple regulation
systems, such as an integrated network of microRNAs (miR-
NAs) and transcription factors [5, 6]. The emerging role of
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miRNAs, a class of single-stranded noncoding RNAs of 19–25
nucleotides in length, in regulation of inflammatory response
has been already reported in chronic pulmonary diseases
such as asthma [7] and chronic obstructive pulmonary
disease [8]. In sarcoidosis, altered miRNA pattern has been
reported in lung tissues [9], peripheral blood mononuclear
cells [9–11], and serum [10]. However, there is no infor-
mation regarding the miRNA pattern in bronchoalveolar
lavage (BAL) cells and their regulatory capability related
to cytokine/chemokine-receptor network in pulmonary sar-
coidosis. Also, a Th1-transcription factor T-bet has emerged
as key regulator of crucial immune genes such as interferon-
(IFN-) 𝛾 and chemokine receptor CXCR3 in sarcoid inflam-
mation [12–14] as well as in other inflammatory conditions
[15–17].However, no information about the possible coopera-
tion of thisTh1-transcription factor and inflammation-related
microRNAs in regulation of cytokine/chemokine-receptor
network in BAL cells in sarcoidosis exists yet.
In this study, we aimed to investigate the gene expression
pattern of candidate inflammation-related miRNAs in BAL
cells obtained from sarcoidosis patients and control subjects.
In order to assess the possible contributions of miRNAs
as posttranscriptional regulators and T-bet as a driver Th1-
transcription factor on sarcoid inflammation, we searched for
relationships between miRNAs and T-bet with sarcoidosis-
associated cytokine/chemokine-receptor network in BAL
cells obtained from patients with sarcoidosis and subgroups
with progressing and regressing disease as assessed by 2-year
follow-up. We believe that understanding the transcriptional
and posttranscriptional regulation of cytokine/chemokine-
receptor network could shed light on the cause and progres-
sion of pulmonary sarcoidosis and other inflammatory and
autoimmune diseases and eventually lay the groundwork for
therapeutic options.
2. Materials and Methods
2.1. Subjects. Patients were further subdivided according
to the disease development as assessed by 2-year follow-
up. BAL was performed according to a standard protocol
[18] in 48 patients with pulmonary sarcoidosis (S) and
14 control subjects (C) of Czech origin. The diagnosis of
sarcoidosis was determined in compliance with the criteria
from the Statement on Sarcoidosis [19]. No patient received
corticosteroid treatment before BAL. Patients were further
subdivided according to the disease development as assessed
by the 2-year follow-up: (i) patients with progressing disease
(Prog, 𝑛 = 20) and (ii) those where the regression was
achieved (Reg, 𝑛 = 28). The control group consisted of 14
subjects undergoing BAL as a part of clinical investigation for
psychogenic cough, cough associated with gastroesophageal
reflux disease and lung hypertension. For clinical and labora-
tory characteristics of enrolled patients and control subjects,
see Table 1.
All patients gave their informed consent for the use
of BAL, taken primarily for diagnostic evaluation, for the
purpose of this study. The local ethical committee of Palacky´
University and Faculty Hospital, Olomouc, approved the
study.
2.2. BAL Sample Processing, miRNA/mRNA Isolation, and
Reverse Transcription. BAL cells were separated from the
fluid by centrifugation and total RNA was isolated from
unseparated BAL cells with mirVana miRNA kit (Ambion,
Austin, USA); RNA quality and quantity were measured
by 2100 Bioanalyzer using RNA 6000 Nano assays (Agilent
Technologies, Palo Alto, USA). The reverse transcription of
miRNA was performed with TaqMan microRNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA) using
stem-loop RT primers, ensuring RT efficiency and specificity
[20] according to the manufacturer’s instructions. The reac-
tions were incubated for 30min at 16∘C, 30min at 42∘C,
and 5min at 85∘C. The resulting cDNA was stored at −20∘C
until use. The reverse transcription of mRNA was performed
with Transcriptor First Strand cDNA Synthesis Kit with
anchored dT primers (Roche Applied Science, Indianapolis,
USA) according to the manufacturer’s recommendation.The
reactions were incubated for 10min at 65∘C, 60min at 50∘C,
and 5min at 85∘C. The resulting cDNA was stored at −20∘C
until use.
2.3. Measurement of miRNA/mRNA Expression by Quantita-
tive RT-PCR. The gene expression for each miRNA and
mRNA in BAL cells was investigated by qRT-PCR using spe-
cific primers and probes (see Table S1 and Table S2, in Supple-
mentaryMaterial available online at http://dx.doi.org/10.1155/
2015/121378). qRT-PCR for each individual miRNA was
performed in a 20𝜇L reaction mixture that included 1.3𝜇L
of diluted RT product, 1 𝜇L of 20X TaqMan Individual
microRNA assay, 10 𝜇L of 2X TaqMan Universal PCRMaster
Mix, No AmpErase UNG (Applied Biosystems), and 7.7 𝜇L
of nuclease-free water. qRT-PCR for each individual mRNA
expression was performed as described previously [21]. All
reactionswere performed onRotorGene3000 system (Qiagen
Inc., Valencia, CA, USA); the reaction steps were as follows:
95∘C for 10min, followedby 40 cycles at 95∘C for 15 s and 60∘C
for 1min. The relative miRNA and mRNA expression levels
were calculated by a second-derivative method (RotorGene
Software 6.1.81, Corbett, Sydney, Australia); cDNA from
human universal reference RNA (Stratagene, La Jolla, CA,
USA) was used as a calibrator. A reference gene for miRNA
analysis was endogenous control Mammalian U6 and for
mRNA a reference gene PSMB2 [21]. Changes in expression
levels are presented as mean relative expression with 95%
confidence interval (CI).
2.4. Selection of Candidate miRNAs and Identification of
Binding Sites. The miRNA pathway analysis web server
DIANA-mirPath v.3 (http://www.microrna.gr/miRPathv3/)
[22] was used to nominate the candidate inflammation-
related miRNAs based on their possible involvement in
cytokine-chemokine interaction pathway. For the identifica-
tion of binding sites between candidatemiRNAs andmRNAs,
we used the mirSystem [23] (Table S3, Supplementary Mate-
rial). This web-based tool integrates the seven most often
used target gene prediction algorithms: DIANA, miRanda,
miRBridge, PicTar, PITA, rna22, and TargetScan. Moreover,
it contains validated data of interactions between particular
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Table 1: Clinical and laboratory data of enrolled patients with pulmonary sarcoidosis.
Characteristics Sarcoidosis Regression Progression Controls
(𝑁 = 48) (𝑁 = 28) (𝑁 = 20) (𝑁 = 14)
Age, yrs 47.9 (29–72) 45.8 (29–70) 50.9 (32–72) 39.6 (19–63)
Sex (male/female) 23/25 12/16 11/9 9/5
Smoking (y/n/ex) 0/37/11 0/20/8 0/17/3 0/9/5
Pulmonary/pulmonary plus
extrapulmonary involvement 35/13 18/10 17/3 —
CXR stages (I/II) 15/33 10/18 5/15 —
Lo¨fgren’s syndrome (y/n) 7/41 4/24 3/17 —
BALF differential count†
%macrophages 75.6 ± 5.8(40.0–94.0)
74.3 ± 6.6
(40.0–94.0)
77.5 ± 4.5
(60.5–87.4)
92.2 ± 13.5
(83.8–97.4)
% lymphocytes 21.6 ± 5.5(4.6–49.0)
22.8 ± 6.2
(6.0–49.0)
19.9 ± 4.6
(4.6–36.0)
6.2 ± 2.3
(1.6–11.0)
% neutrophils 2.1 ± 1.6(0.0–18.0)
2.3 ± 1.8
(0.0–18.0)
1.8 ± 1.2
(0.0–10.0)
1.5 ± 0.8
(0.3–6.0)
% eosinophils 1.3 ± 1.9(0.0–17.3)
1.3 ± 1.6
(0.0–17.0)
1.4 ± 1.9
(0.0–17.3)
0.3 ± 0.1
(0.3–0.6)
% CD3+# 83.6 ± 6.4(48.0–98.0)
83.8 ± 7.1
(48.0–96.0)
83.3 ± 5.7
(54.0–98.0)
74.1 ± 7.2
(40.0–92.0)
% CD4+# 64.9 ± 8.8(23.0–92.0)
66.9 ± 8.9
(27.0–92.0)
62.0 ± 8.9
(23.0–86.0)
45.7 ± 7.3
(22.0–67.0)
% CD8+# 16.8 ± 5.7(2.0–50.0)
14.4 ± 4.9
(2.0–42.0)
20.3 ± 6.4
(4.0–50.0)
27.4 ± 5.5
(14.0–51.0)
% CD19+# 1.03 ± 1.2(0.0–14.0)
0.9 ± 1.3
(0.0–14.0)
1.2 ± 1.1
(0.0–8.0)
1.2 ± 0.6
(0.0–3.0)
BALF CD4+/CD8+ ratio 6.8 ± 3.6(0.8–46.0)
7.9 ± 4.2
(1.1–46.0)
5.3 ± 2.6
(0.8–21.3)
2.0 ± 0.5
(0.5–3.7)
BALF: bronchoalveolar lavage fluid;𝑁: number of patients; n: no; y: yes; ex: ex-smoker; CXR: chest X-ray; —: not relevant.
Data are presented as mean ± SD (minimum and maximum in parentheses).
†Data were not available for four patients.
#% of CD3, CD4, CD8, and CD19 refers to total lymphocyte counts.
miRNA and its target genes from TarBase and miRecords
databases.
2.5. Clustering Using Kohonen Self-Organizing Neural Net-
works. Kohonen self-organizing neural network (self-organ-
izing maps, SOM), a clustering tool, was applied to find
clusters of input data that are very close to each other [24].The
input data (the whole data set including miRNA and mRNA
expression of all studied molecules) for each sarcoidosis
patient were transformed to vectors, which were recorded in
the neural network. Neurons in the cortex were organized
in 2D; only the adjacent neurons were interconnected. If the
data clustered to neurons in SOMshow the internal clustering
structure corresponding to the analyzed subgroups (in our
case progressing and regressing disease), the data set has high
potential to contain relevant biological relationships.
2.6. miRNA/mRNA Correlation Analysis. Correlation matri-
ces were computed to investigate the relationships between
miRNA expression andmRNA expression ofT-bet andmem-
bers of sarcoidosis-associated cytokine/chemokine-receptor
network represented by Spearman correlation coefficient.The
correlation matrices were graphically presented using heat
maps, where a hierarchical agglomerative clustering analysis
was performed to show the relationships between groups
of miRNA and mRNA in the form of clusters. The colour
of each cell of the heat map corresponds to the value of
Spearman correlation coefficient between given miRNA and
corresponding mRNA.
2.7. Circos Diagrams for Visualization of miRNA/mRNA Rela-
tionships. To graphically represent the relationships between
miRNAs, mRNAs, and T-bet, a Chord diagram generated
in Circos system [25] (http://mkweb.bcgsc.ca/tableviewer/)
was applied for (i) sarcoidosis patients and subgroups of
patients with (ii) progressing sarcoidosis and (iii) regressing
sarcoidosis. In the diagram, only significant correlations
are depicted (𝑃 < 0.05). The intensity of correlations
(𝑤) between individual miRNA-mRNA pairs corresponds to
absolute value of Spearman correlation coefficient (𝑟
𝑠
), for
which the mathematical transformation was performed to
accentuate the differences in the intensities of correlations.
For the transformation, the following formula was used:
𝑤 = 1 + [10 × (𝑟
𝑠
− 𝑡)]
2
, (1)
where 𝑡 represents the threshold for the highest significant 𝑃
value.
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2.8. miRNA/mRNA/T-bet Network Analysis. For schematic
representation of the relationships between miRNAs, T-
bet, and cytokines/chemokines/receptors, we constructed
weighted gene coexpression network [26]. Further, an algo-
rithm based on analysis of the nearest neighbors between the
studied molecules (represented as vertices) was applied [27].
The larger vertices (spheres) in the network havemore nearest
neighbors based on correlation analysis than smaller vertices.
Only edges connecting the nearest neighbors (pairs with the
highest correlations) were preserved. In other words, the
size of the vertices (spheres) and connection among vertices
show relationships between the investigated molecules in the
network.
2.9. Statistical Analysis. Data analysis was performed using
GraphPad Prism 5.01 (GraphPad Software, La Jolla, CA,
USA) and SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Dif-
ferences in miRNA and mRNA levels between the cohorts
were assessed by nonparametric Kruskal-Wallis one-way
analysis-of-variance-by-ranks test; nonparametric Mann-
Whitney test was utilized to determine significant differences
between two groups. Spearman correlation coefficient and
its corresponding 𝑃 values were computed using R statistical
software package (http://www.r-project.org/). A 𝑃 value <
0.05 was considered significant.
3. Results
3.1. Selection of Studied miRNAs. Candidate miRNAs were
selected based on their possible involvement in the regulation
of inflammatory response, particularly cytokine/chemokine-
receptor network. Using DIANA-mirPath v.3, we nominated
25 candidate miRNAs (miR-let-7c, let-7d, miR-21, miR-24,
miR-25, miR-92a, miR-125a, miR-126, miR-133a, miR-146a,
miR-148a, miR-150, miR-155, miR-181a, miR-199a, miR-202,
miR-204, miR-206, miR-212, miR-214, miR-222, miR-223,
miR-302c, miR-424, and miR-503) targeting cytokine/che-
mokine-receptor network (see Figure S1, Supplementary
Material), involving many of the cytokines/chemokines and
their receptors associated with sarcoidosis. A list of miRBase
ID numbers and other details on studied miRNAs are stated
in Table S1 (Supplementary Material); the miRNAs having
(3󸀠-UTR) “seed region” for binding to the studied mRNA are
stated in Table S3 (Supplementary Material).
3.2. miRNA Expression Profiling
3.2.1. Analysis of miRNA Expressions in Sarcoidosis Patients
and Control Subjects. In order to investigate the miRNA
expression pattern, the expression levels of miR-let-7c, let-
7d, miR-21, miR-24, miR-25, miR-92a, miR-125a, miR-126,
miR-133a, miR-146a, miR-148a, miR-150, miR-155, miR-181a,
miR-199a, miR-202, miR-204, miR-206, miR-212, miR-214,
miR-222, miR-223, miR-302c, miR-424, and miR-503 were
determined in BAL cells obtained from sarcoidosis patients
and control subjects.
When compared to control subjects, a higher number of
miR-150 (𝑃 < 0.001) and miR-146a (𝑃 = 0.006) (Table 2,
Figure 2(a)) transcripts and lower miR-202 (𝑃 = 0.036),
miR-204 (𝑃 = 0.031), and miR-222 (𝑃 = 0.012) (Table 2,
Figure 2(a)) expression were detected in sarcoidosis patients.
No difference in expression levels of other studied miRNAs
was observed between sarcoidosis and control subjects (Fig-
ure 1(a)).
3.2.2. Analysis of miRNA Expressions in Sarcoidosis Patients
with Progressing/Regressing Disease. In order to investigate
the miRNA expression pattern in sarcoidosis patients sub-
divided according to disease outcome after 2-year follow-
up, the expression levels of a set of candidate miRNAs were
determined in BAL cells from progressing and regressing
sarcoidosis. To exclude the notion that variations in the levels
of expression of transcripts might be related to changes in cell
populations, we investigated the distribution of the absolute
and relative number of BAL macrophages and lymphocytes
and revealed no difference between subgroups of patients
with progressing and regressing sarcoidosis (𝑃 > 0.05).
When comparing to regressing sarcoidosis, elevated
expression of miR-155 (𝑃 = 0.017) and let-7c (𝑃 = 0.039)
(Table 2, Figure 2(b)) was detected in progressing disease. No
difference in expression levels of other studied miRNAs was
observed between patients with progressing and regressing
sarcoidosis (Figure 1(a)).
3.3. mRNA Expression Profiling
3.3.1. Analysis of mRNA Expressions in Sarcoidosis Patients
and Control Subjects. In order to investigate the mRNA ex-
pression pattern in sarcoidosis, the expression levels of CCL2,
CCL3, CCL4, CCL5, CCL7, CCL8, CCL13, CCL19, CXCL2,
CXCL3, CXCL9, CXCL10, CXCL11, CXCL12, CXCL16, CCR1,
CCR2A, CCR2B, CCR5, CXCR3, CXCR4, CXCR6, CXCR7,
IL2, IL2RA, IL2RB, IL15RA, IFNG, and T-bet were deter-
mined in BAL cells obtained from sarcoidosis patients and
control subjects.
When comparing to control subjects, the expression
levels of CC chemokines CCL3 (𝑃 = 0.043), CCL4 (𝑃 =
0.034), CCL5 (𝑃 < 0.001), and CCL8 (𝑃 = 0.031) and CXC
chemokines CXCL9 (𝑃 < 0.001), CXCL10 (𝑃 = 0.002), and
CXCL11 (𝑃 = 0.008) were found to be elevated in sarcoidosis
patients (Table 3, Figure 1(b)). Among chemokine receptors,
mRNA expressions of CCR2-var.A (𝑃 = 0.018), CCR5 (𝑃 =
0.003), CXCR3 (𝑃 < 0.001), and CXCR6 (𝑃 < 0.001)
were elevated in sarcoidosis patients (Table 3, Figure 1(b)).
Among cytokines/cytokine receptors, the expression levels of
IL2 (𝑃 < 0.001), IL2RB (𝑃 = 0.049), IL15RA (𝑃 = 0.048),
and IFNG (𝑃 < 0.001) were elevated in sarcoidosis patients
(Table 3, Figure 1(b)).T-betmRNA expression was also found
to be elevated in sarcoidosis patients (𝑃 = 0.006) comparing
to control subjects (Table 3, Figure 1(b)).
3.4. Self-Organizing Neural Networks for Sarcoidosis Patients.
In order to assess the inner data structure in our data sets,
we applied the Kohonen SOM. The unsupervised clustering
analysis classified the sarcoidosis patients into the follow-
ing clusters represented by neurons (hexagons): (1) green
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Table 2: Comparison of miRNA expression profiles between sarcoidosis (S) patients, subdivided according to the outcome after 2-year
follow-up (Reg: regression; Prog: progression), and control subjects (C). All the data are presented asMean Expression Level (95% confidence
interval). Results are expressed relative to levels of endogenous U6 miRNA.𝑁: number of patients. Bold font indicates significant 𝑃 value.
S Reg S Prog S C 𝑃 𝑃 𝑃
(𝑁 = 48) (𝑁 = 28) (𝑁 = 20) (𝑁 = 14) (Kruskal-Wallis) S versus C Reg versus Prog
miR-let-7c-5p 0.058(0.051–0.066)
0.051
(0.042–0.060)
0.069
(0.056–0.082)
0.069
(0.052–0.087) 0.127 0.239 0.039
miR-let-7d-5p 0.136(0.118–0.154)
0.124
(0.100–0.147)
0.153
(0.126–0.181)
0.155
(0.120–0.190) 0.250 0.256 0.103
miR-21-5p 2.022(1.618–2.427)
1.676
(1.300–2.051)
2.508
(1.693–3.323)
2.023
(1.253–2.794) 0.585 0.833 0.161
miR-24-3p 0.522(0.462–0.582)
0.488
(0.409–0.567)
0.570
(0.473–0.667)
0.571
(0.432–0.711) 0.432 0.405 0.174
miR-25-3p 0.110(0.071–0.150)
0.117
(0.050–0.184)
0.101
(0.077–0.124)
0.089
(0.042–0.137) 0.485 0.434 0.191
miR-92a-3p 0.364(0.312–0.416)
0.319
(0.255–0.384)
0.421
(0.336–0.506)
0.362
(0.272–0.452) 0.277 0.814 0.061
miR-125a-5p 0.044(0.034–0.054)
0.046
(0.029–0.062)
0.042
(0.031–0.052)
0.058
(0.020–0.096) 0.982 0.814 0.770
miR-126-3p 0.054(0.005–0.102)
0.077
(0.007–0.160)
0.021
(0.012–0.030)
0.057
(0.004–0.118) 0.992 0.860 0.810
miR-133a-3p 0.012(0.010–0.015)
0.012
(0.008–0.015)
0.013
(0.009–0.017)
0.014
(0.010–0.018) 0.589 0.248 0.557
miR-146a-5p 0.304(0.266–0.342)
0.294
(0.235–0.352)
0.319
(0.271–0.366)
0.196
(0.135–0.257) 0.020 0.006 0.331
miR-148a-3p 0.061(0.050–0.072)
0.056
(0.042–0.069)
0.068
(0.049–0.087)
0.074
(0.050–0.097) 0.507 0.342 0.268
miR-150-5p 0.280(0.219–0.340)
0.277
(0.199–0.355)
0.283
(0.179–0.386)
0.093
(0.061–0.125) <0.001 <0.001 0.983
miR-155-5p 0.200(0.170–0.231)
0.169
(0.138–0.200)
0.244
(0.187–0.300)
0.168
(0.126–0.210) 0.111 0.550 0.017
miR-181a-5p 0.106(0.091–0.121)
0.102
(0.084–0.120)
0.112
(0.085–0.139)
0.122
(0.091–0.153) 0.650 0.263 0.630
miR-199a-5p 0.012(0.010–0.014)
0.011
(0.008–0.014)
0.013
(0.009–0.016)
0.016
(0.007–0.024) 0.919 0.748 0.532
miR-202-3p 0.009(0.008–0.011)
0.010
(0.007–0.013)
0.013
(0.006–0.020)
0.014
(0.009–0.019) 0.173 0.036 0.564
miR-204-5p 0.008(0.006–0.010)
0.006
(0.005–0.007)
0.010
(0.005–0.015)
0.011
(0.007–0.015) 0.030 0.031 0.061
miR-206 0.026(0.002–0.064)
0.039
(0.003–0.101)
0.010
(0.001–0.021)
0.005
(0.003–0.007) 0.999 0.928 0.963
miR-212-3p 0.010(0.008–0.013)
0.010
(0.008–0.012)
0.011
(0.006–0.017)
0.012
(0.009–0.016) 0.490 0.158 0.705
miR-214-3p 0.009(0.006–0.011)
0.008
(0.006–0.010)
0.010
(0.005–0.014)
0.010
(0.005–0.014) 0.968 0.866 0.621
miR-222-3p 0.038(0.029–0.048)
0.059
(0.047–0.072)
0.065
(0.050–0.080)
0.062
(0.052–0.071) 0.059 0.012 0.668
miR-223-3p 0.808(0.679–0.936)
0.815
(0.615–1.014)
0.798
(0.644–0.951)
0.901
(0.695–1.106) 0.692 0.270 0.826
miR-302c-3p 0.061(0.048–0.074)
0.060
(0.041–0.079)
0.065
(0.046–0.083)
0.089
(0.034–0.143) 0.820 0.427 0.631
miR-424-5p 0.103(0.002–0.289)
0.013
(0.002–0.025)
0.009
(0.006–0.012)
0.018
(0.005–0.031) 0.426 0.143 0.905
miR-503-5p 0.038(0.030–0.046)
0.041
(0.030–0.052)
0.035
(0.023–0.046)
0.058
(0.022–0.094) 0.480 0.643 0.112
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Table 3: Comparison of mRNA expression profiles of studied cytokines, chemokines, chemokine receptors, and T-bet between sarcoidosis
(S) patients, subdivided according to the outcome after 2-year follow-up (Reg: regression; Prog: progression), and control subjects (C). All
the data are presented as Mean Expression Level (95% confidence interval). Results are expressed relative to levels of a housekeeping gene
PSMB2.𝑁: number of patients. Bold font indicates significant 𝑃 value.
S Reg S Prog S C 𝑃 𝑃 𝑃
(𝑁 = 48) (𝑁 = 28) (𝑁 = 20) (𝑁 = 14) (Kruskal-Wallis) C versus S Reg versus Prog
CCL2 0.058(0.051–0.066)
0.051
(0.042–0.060)
0.069
(0.056–0.082)
0.069
(0.052–0.087) 0.950 0.602 0.875
CCL3 0.136(0.118–0.154)
0.124
(0.100–0.147)
0.153
(0.126–0.181)
0.155
(0.120–0.190) 0.110 0.043 0.237
CCL4 2.022(1.618–2.427)
1.676
(1.300–2.051)
2.508
(1.693–3.323)
2.023
(1.253–2.794) 0.157 0.034 0.746
CCL5 0.522(0.462–0.582)
0.488
(0.409–0.567)
0.570
(0.473–0.667)
0.571
(0.432–0.711) 0.002 <0.001 0.834
CCL7 0.110(0.071–0.150)
0.117
(0.050–0.184)
0.101
(0.077–0.124)
0.089
(0.042–0.137) 0.500 0.152 1.000
CCL8 0.364(0.312–0.416)
0.319
(0.255–0.384)
0.421
(0.336–0.506)
0.362
(0.272–0.452) 0.147 0.031 1.000
CCL13 0.044(0.034–0.054)
0.046
(0.029–0.062)
0.042
(0.031–0.052)
0.058
(0.020–0.096) 0.861 0.939 0.420
CCL19 0.054(0.005–0.102)
0.077
(0.007–0.160)
0.021
(0.012–0.030)
0.057
(0.004–0.118) 0.477 0.216 0.403
CXCL2 0.012(0.010–0.015)
0.012
(0.008–0.015)
0.013
(0.009–0.017)
0.014
(0.010–0.018) 0.429 0.414 0.161
CXCL3 0.304(0.266–0.342)
0.294
(0.235–0.352)
0.319
(0.271–0.366)
0.196
(0.135–0.257) 0.069 0.608 0.011
CXCL9 0.061(0.050–0.072)
0.056
(0.042–0.069)
0.068
(0.049–0.087)
0.074
(0.050–0.097) 0.005 <0.001 0.670
CXCL10 0.280(0.219–0.340)
0.277
(0.199–0.355)
0.283
(0.179–0.386)
0.093
(0.061–0.125) 0.009 0.002 0.925
CXCL11 0.200(0.170–0.231)
0.169
(0.138–0.200)
0.244
(0.187–0.300)
0.168
(0.126–0.210) 0.045 0.008 0.754
CXCL12 0.106(0.091–0.121)
0.102
(0.084–0.120)
0.112
(0.085–0.139)
0.122
(0.091–0.153) 0.180 0.101 0.204
CXCL16 0.012(0.010–0.014)
0.011
(0.008–0.014)
0.013
(0.009–0.016)
0.016
(0.007–0.024) 0.241 0.982 0.612
CCR1 0.009(0.008–0.011)
0.010
(0.007–0.013)
0.013
(0.006–0.020)
0.014
(0.009–0.019) 0.289 0.277 0.112
CCR2-var.A 0.008(0.006–0.010)
0.006
(0.005–0.007)
0.010
(0.005–0.015)
0.011
(0.007–0.015) 0.051 0.018 0.241
CCR2-var.B 0.026(0.002–0.064)
0.039
(0.003–0.101)
0.010
(0.001–0.021)
0.005
(0.003–0.007) 0.779 0.444 0.587
CCR5 0.010(0.008–0.013)
0.010
(0.008–0.012)
0.011
(0.006–0.017)
0.012
(0.009–0.016) 0.016 0.003 0.427
CXCR3 0.009(0.006–0.011)
0.008
(0.006–0.010)
0.010
(0.005–0.014)
0.010
(0.005–0.014) 0.002 <0.001 0.691
CXCR4 0.038(0.029–0.048)
0.059
(0.047–0.072)
0.065
(0.050–0.080)
0.062
(0.052–0.071) 0.295 0.152 0.271
CXCR6 0.808(0.679–0.936)
0.815
(0.615–1.014)
0.798
(0.644–0.951)
0.901
(0.695–1.106) <0.001 <0.001 0.616
CXCR7 0.061(0.048–0.074)
0.060
(0.041–0.079)
0.065
(0.046–0.083)
0.089
(0.034–0.143) 0.667 0.392 0.417
IL2 0.103(0.002–0.289)
0.013
(0.002–0.025)
0.009
(0.006–0.012)
0.018
(0.005–0.031) <0.001 <0.001 0.730
IL2RA 0.038(0.030–0.046)
0.041
(0.030–0.052)
0.035
(0.023–0.046)
0.058
(0.022–0.094) 0.210 0.051 0.730
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Table 3: Continued.
S Reg S Prog S C 𝑃 𝑃 𝑃
(𝑁 = 48) (𝑁 = 28) (𝑁 = 20) (𝑁 = 14) (Kruskal-Wallis) C versus S Reg versus Prog
IL2RB 0.038(0.029–0.048)
0.059
(0.047–0.072)
0.065
(0.050–0.080)
0.062
(0.052–0.071) 0.131 0.049 0.272
IL15RA 0.808(0.679–0.936)
0.815
(0.615–1.014)
0.798
(0.644–0.951)
0.901
(0.695–1.106) 0.182 0.048 0.530
IFNG 0.061(0.048–0.074)
0.060
(0.041–0.079)
0.065
(0.046–0.083)
0.089
(0.034–0.143) <0.001 <0.001 0.565
T-bet 0.103(0.002–0.289)
0.013
(0.002–0.025)
0.009
(0.006–0.012)
0.018
(0.005–0.031) 0.031 0.006 0.573
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Figure 1: Hierarchical clustering of gene expression data. The rows represent individual (a) miRNAs and (b) mRNAs; the columns represent
individual subject samples (1 column per sample) divided into three cohorts, such as sarcoidosis patients with progressing (red zone) and
regressing (green zone) disease and control subjects (blue zone). The colour represents the gene expression level (blue: low expression, red:
high expression); the expression levels are continuously mapped on the colour scale provided at the top of the figure. The analysis was
performed using the R statistical software package (http://www.r-project.org/).
neurons including only patients with progression, (2) red
neurons including only patients with regression; and (3)
neurons including both classes visualized as interpolation
between red and green colors (Figure 3).
This analysis supports the presence of inner structures in
patient subgroups as assessed by disease outcome, thus sup-
porting the fact that the subgroups differ in miRNA/mRNA
profiles.Three clusters exactly matched patients with regress-
ing sarcoidosis (25%) and one cluster patients with progress-
ing disease (10.4%). Two clusters more or less correspond
to patients with regressing sarcoidosis (27.1%), whereas one
cluster more or less corresponds to patients with progressing
disease (16.7%). On the other hand, two clusters of patients
(20.8%) do not correspond to any class. Interestingly, the
patients with regression formed more clusters than pro-
gressing patients, thus indicating that this subgroup is more
heterogeneous regarding the expression profiles of studied
miRNAs and mRNAs comparing to progressing disease.
3.5. Correlation Analysis of miRNAs, T-bet, and Cytokine/Che-
mokine-Receptor Network. In order to assess the relation-
ships between studied miRNAs and mRNAs in BAL cells,
we performed correlation analysis. To distinguish the degree
of correlation between miRNA-mRNA pairs, we set up
cut-off for Spearman correlation coefficient corresponding
to significant 𝑃 value (𝑃 < 0.05). Since no significant
correlations between the studied molecules were detected
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Figure 2: Distribution of relative miRNA expression (ratio target miRNA/reference endogenous U6miRNA) of (a) five deregulated miRNAs
between sarcoidosis patients (S) and control subjects (C) and (b) two deregulated miRNAs between patients with regressing (Reg) and
progressing (Prog) sarcoidosis. Group means are indicated by horizontal bars; error bars indicate 95% CI.
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Figure 3: Kohonen self-organizing map (SOM) for a whole gene
expression data set in BAL cells obtained from patients with
sarcoidosis. Clustering shows the ratio of occurrence (given as %
of patients/neuron) of two classes (progression and regression) in
individual neurons (green neurons for patients with progression,
red neurons for patients with regression; neurons classifying both
classes are visualized as interpolation between red and green colors).
The bold numbers indicate % of sarcoidosis patients clustered into
particular neuron.
in control group, the Chord diagram for this group is not
presented.
Themost significant correlations in sarcoidosis as a whole
were observed for the following miRNA-mRNA pairs: miR-
212-CXCL10 (𝑃 < 0.001), miR-24-CXCR4 (𝑃 < 0.001), miR-
125a-CCL7 (𝑃 = 0.005), miR-146a-CCL19 (𝑃 = 0.003), miR-
25-CCL2 (𝑃 = 0.002), miR-214-CCL2 (𝑃 = 0.008), miR-
24-CCL5 (𝑃 = 0.010), miR-24-CXCR3 (𝑃 = 0.005), miR-
21-CXCR7 (𝑃 = 0.003), miR-204-IFNG (𝑃 = 0.008), miR-
148a-CXCR4 (𝑃 = 0.003), and miR-155-CXCR4 (𝑃 = 0.003)
(Figure 4(a)). Regarding T-bet, we observed correlations with
CCL5 (𝑃 < 0.001), CXCR3 (𝑃 < 0.001), CXCR4 (𝑃 < 0.001),
CXCR6 (𝑃 < 0.001), IL2 (𝑃 < 0.001), IL2RA (𝑃 < 0.001),
IL2RB (𝑃 < 0.001), IL15RA (𝑃 < 0.001), IFNG (𝑃 < 0.001),
CCR2B (𝑃 = 0.004), CXCL10 (𝑃 = 0.021), and CCR5 (𝑃 =
0.021) (Figure 4(a)).
In progressing disease, relationships for the following
miRNA-mRNA pairs were observed: miR-25-CCL2 (𝑃 <
0.001), miR-126-CCL2 (𝑃 < 0.001), miR-214-CCL2 (𝑃 <
0.001), miR-125a-CCL7 (𝑃 = 0.008), miR-126-CCL7 (𝑃 =
0.009), let-7d-CXCR7 (𝑃 = 0.001), andmiR-126-CXCR7 (𝑃 =
0.009) (Figure 4(b)). T-bet correlated with CCL5 (𝑃 < 0.001),
CXCR3 (𝑃 < 0.001), CXCR4 (𝑃 < 0.001), IL2RB (𝑃 < 0.001),
IL15RA (𝑃 < 0.001), IFNG (𝑃 < 0.001), CXCR6 (𝑃 = 0.005),
CXCL10 (𝑃 = 0.016), CCR2B (𝑃 = 0.029), IL2 (𝑃 = 0.044),
and IL2RA (𝑃 = 0.037) (Figure 4(b)).
In regressing sarcoidosis, we detected correlations among
the following miRNA-mRNA pairs: miR-146a-CCL19 (𝑃 <
0.001), let-7c-CCL19 (𝑃 = 0.007), miR-202-CXCL10 (𝑃 =
0.010), miR-212-CXCL10 (𝑃 = 0.002), miR-92a-CXCL12
(𝑃 = 0.008), miR-148a-CXCR4 (𝑃 = 0.002), miR-24-IL2RB
(𝑃 = 0.006), and miR-25-IL2RB (𝑃 = 0.006) (Figure 4(c)).
Moreover, T-bet correlated with CXCR3 (𝑃 < 0.001), IL2
(𝑃 < 0.001), IL2RA (𝑃 < 0.001), IL2RB (𝑃 < 0.001), IL15RA
(𝑃 < 0.001), IFNG (𝑃 < 0.001), CCL13 (𝑃 = 0.004), CXCL2
(𝑃 = 0.004), CXCR6 (𝑃 = 0.007), CXCL11 (𝑃 = 0.013), CCL5
(𝑃 = 0.018), CCR2A (𝑃 = 0.033), CCR2B (𝑃 = 0.023), and
CXCR4 (𝑃 = 0.017) (Figure 4(c)).
In sarcoidosis patients, certain genes correlated with both
T-bet andmiRNAs simultaneously (Figure 4(d)). Correlation
with both T-bet and miRNAs was observed for CCL5,
CXCL10, CXCR3, CXCR4, CXCR6, IL2, IL15RA, and IFNG.
In progressing sarcoidosis, correlation with both T-bet and
miRNAs was observed for CXCR3 and IL2RB (Figure 4(b),
Figure S2, Supplementary Material), whereas in regressing
sarcoidosis T-bet correlated with CCL5, CCL13, CXCL11,
CCR2A, CCR2B, CXCR3, CXCR4, IL2, IL2RB, IL15RA, and
IFNG (Figure 4(c), Figure S2, Supplementary Material).
3.6. Weighted Gene Coexpression Network Analysis for
miRNA-mRNA Relationships. In order to better characterize
the relationships between studied miRNAs, mRNAs, and
T-bet, we performed weighted gene coexpression network
analysis.
The close relationships in sarcoidosis as a whole were
found between T-bet and IL2RB, IL15RA, and CXCR3, which
was related to CXCR6 and IFNG (Figure 5(a)). IFNG related
to IL2 and CCL5 and also to miR-204. We observed rela-
tionships also between miR-212-CXCL10 and miR-21-CCR5.
ConsideringmiRNAs, we found relationships between let-7d,
miR-155,miR-24, andmiR-25 and betweenmiR-202,miR-212,
miR-424, andmiR-503 (Figure 5(a)).
In progressing sarcoidosis, T-bet related to CCL5,
IL2RB, IL15RA, and IFNG (Figure 5(b)). Relationships
were observed also between miR-212 and IFNG-induced
chemokinesCXCL9 andCXCL11. In addition, CXCL11 related
to miR-204. Relationships were observed also between miR-
424 and CCL4 and CXCL10, whereas miR-148a related to
CCR2A. Among miRNAs, relationships were found between
miR-21, miR-25, miR-148a, miR-92a, and let-7d and between
miR-146a,miR-222, and let-7c (Figure 5(b)).
In regressing sarcoidosis, relationships were observed
between T-bet and IL2RB, IL15RA, CXCR3, IL2, and IFNG
(Figure 5(c)). We observed relationships also between miR-
212 and CXCL10 and between miR-503 and CCR2A. Among
miRNAs, relationships were detected between let-7d, miR-
148a,miR-24, andmiR-25, betweenmiR-146a, miR-150,miR-
222, and let-7c, and between miR-212,miR-202, andmiR-503
(Figure 5(c)).
Regarding control group, the investigatedmolecules were
not closely related to each other (small vertices) and their
relationship pattern differed from sarcoidosis-associated pat-
tern (Figure 5(d)).
4. Discussion
This is the first study investigating the suggested contri-
bution of both transcriptional and posttranscriptional con-
trol to deregulated cytokine/chemokine-receptor network
in pulmonary sarcoidosis. Our correlation network anal-
ysis revealed that both inflammatory-related microRNAs
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Figure 4: Continued.
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Figure 4: miRNA-mRNA-T-bet correlations in BAL cells obtained from (a) sarcoidosis patients and their subgroups with (b) progressing and
(c) regressing disease are represented using Chord diagrams (circular graphs). In the Chord diagram, the intensity of the band corresponds
to the significance of the correlation between particular miRNA-mRNA pair and T-bet-mRNA pair as assessed using Spearman’s rank
correlation; only significant correlations (𝑃 < 0.05) are visualized. (d) A hierarchical agglomerative clustering analysis presented using heat
map for sarcoidosis as a whole. The colour of each cell of the heat map corresponds to value of Spearman correlation coefficient between
given miRNA-mRNA pairs. % ly: % of lymphocytes in BAL fluid; abs ly: absolute number of lymphocytes/1mL BAL fluid.
and a key Th1-transcription factor T-bet may contribute to
deregulated cytokine/chemokine-receptor network in sar-
coid BAL cells, whereas contributions of transcriptional and
posttranscriptional regulation differ between progressing and
regressing disease as assessed by 2-year follow-up.We also for
the first time investigated the gene profile of inflammation-
related miRNAs in BAL cells and revealed altered miRNA
pattern in BAL cells obtained from patients with sarcoidosis
comparing to control subjects and also from patients with
progressing versus regressing disease.
In sarcoidosis pathogenesis, the crucial role is attributed
to inflammatory cytokines and chemokines, which direct cir-
culating leukocytes to the sites of inflammation and control
leukocyte activation and cytokine production, angiogenesis,
andTh cell polarization [4, 28, 29]. In view of the crucial role
of cytokines, chemokines, and their receptors in the patho-
genesis of sarcoidosis, a fundamental question arises: how the
cytokine/chemokine-receptor network is regulated. There is
first evidence that cytokines and chemokines are regulated
by both transcriptional and posttranscriptional mechanisms
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Figure 5: A weighted gene coexpression network analysis of miRNA-mRNA-T-bet relationships in BAL cells obtained from (a) sarcoidosis
patients and their subgroups with (b) progressing and (c) regressing disease and from (d) control subjects. The studied molecules are
represented as vertices (spheres), where larger vertices in the network have more nearest neighbors than smaller ones. Only edges connecting
the nearest neighbors (pairs with the highest correlations) were preserved.
allowing for rapid and transient production in response to
a variety of stimuli [30, 31]. In line with this observation,
we hypothesized that the regulation of cytokine/chemokine-
receptor network in BAL cells also involves coordinated par-
ticipation of multiple regulatory systems, including miRNAs
and a key sarcoidosis-associated Th1-transcription factor T-
bet.
However, miRNAs pattern in BAL cells has not been
investigated yet. We therefore investigated for the first time
expression pattern of inflammation-related miRNAs in BAL
cells and revealed downregulated miR-202 and miR-204
and upregulated miR-146a, miR-150, and miR-222 expres-
sion in sarcoidosis comparing to controls. When comparing
progressing to regressing sarcoidosis, a higher number of
miR-155 and let-7c transcripts were detected in progressing
sarcoidosis. All detected miRNAs associated with sarcoidosis
were already associated with regulation of inflammatory
response. Inflammatory miR-155 and miR-146a were found
to be upregulated by NF-𝜅B [32, 33], miR-150 involved
in pulmonary inflammation [34], miR-202 in rheumatoid
arthritis [35], and miR-204 in the production of inflamma-
tory mediators and apoptosis [36]. MiR-222 contributed to
inflammation-mediated neovessel formation [37], and let-7c
regulated allergic airway inflammation [38]. Moreover, miR-
204 was also found to be deregulated in sarcoid lung tissues
reported by Crouser et al. [9]. Interestingly, when comparing
the miRNA profile in sarcoid BAL cells obtained in this study
with profile reported in sarcoid lung tissues [9], we obtained
different pattern of top-deregulated miRNAs (miR-92a, miR-
125a, miR-126, miR-181a, miR-206, and miR-302) found in
sarcoid lung tissues, thus supporting the fact that miRNA
expression signatures vary depending on the tissues and cell
types examined.
However, it is still unclear how miRNAs regulate
cytokines, because 3󸀠-untranslated region (3󸀠-UTR) of most
cytokines lacks critical “seed region” for binding to mRNA
[39]. Current studies showed that cytokine and other immune
genes may be regulated by other elements (e.g., ARE
machinery components) [40] or through highly biologically
functional “nonseed” miRNA target sites, containing single
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mismatches, GU wobbles, insertions, or deletions in the
seed-match regions [41–43]. These “nonseed” miRNA target
sites represent up to 50% of all miRNA-mRNA interac-
tions and remain uncovered, despite their functional sig-
nificance, using current target prediction algorithms [39].
Importantly, miRNA regulation may not be directly at the
cytokine/chemokine or receptor level but rather at upstream
or downstream steps in the pathway. These facts may explain
our observation of correlation between numerous miRNAs
and cytokine expression (e.g., CXCR4 and miR-24), where
no binding site was discovered by prediction algorithms as
well as numerous positive correlations between miRNAs and
cytokine and chemokine expression (e.g., CCL2 and miR-
214) as reported also in other studies [44, 45]. Moreover, the
unique role of miRNAs in inflammation is that the miRNAs
modulate the expression of target genes to an optimum level
rather than participating in on/off decisions [40].
Besides posttranscriptional regulation by miRNAs,
also transcriptional control by transcription factors may
contribute to deregulated cytokine/chemokine-receptor
network in pulmonary sarcoidosis. We recently reported
crucial role for a Th1-transcription factor T-bet, which
has emerged as key regulator of IFNG and chemokine
receptor CXCR3 and other immune genes in sarcoid
inflammation [12]. In the present study, we searched
for evidence of possible participation of transcriptional
and posttranscriptional regulation by miRNAs and T-bet
in controlling the inflammation in sarcoid BAL cells. Our
correlation analysis revealed relationship ofT-bet and sarcoid
inflammation, namely, its association with key sarcoidosis-
associated cytokine IFNG, and receptors IL2RB, IL15RA,
CXCR3, and CXCR6, regardless of the disease outcome.
Importantly, the relationships between T-bet and par-
ticular miRNAs regarding the chemokine network changed
between subgroups of patients, who differed in disease out-
come after 2-year follow-up. In progressing sarcoidosis, T-bet
correlatedwithCCL5, CXCR4, andCXCR7.We also observed
positive correlations between numerousmiRNAs and expres-
sion of CCL2, CCL7, and CXCL12 and negative correlation
with CCL5, CXCR3, CXCR4, and CXCR7 expression in
progressing disease. In regressing disease, T-bet showed less
pronounced correlation with IL2 and receptors CXCR4,
CXCR7, and IL2RA than in progression. AlsomiRNApattern
changed; in regression, the correlation analysis revealed
positive correlation between miR-146a and CCL19 as well
as miR-148a and CXCR4. Our analysis therefore nominated
CCL2 and CCL5, both chemoattractants of mononuclear and
mast cells [46], as well as CCL19, a chemokine implicated in
T-lymphocyte recruitment [47], as key candidate chemokines
associated with prognosis of pulmonary sarcoidosis. Simi-
larly, CXCR4 and CXCR7 and their ligand, CXCL12, playing
a role in regulation of leukocyte mobilization and trafficking
[48, 49], deserve further investigation.
To better characterize the network of inflammation-
related miRNAs, T-bet, and cytokine/chemokine-receptor
network in sarcoid BAL cells, we performed weighted cor-
relation network analysis. This analysis further supported
the crucial relationships between T-bet, CCL5, IFNG, IL2RB,
and IL15RA, together with let-7d andmiR-202 in progressing
sarcoidosis. In regressing disease, T-bet was more closely
related to CXCR3 and less to IFNG and CCL5 than in
progressing disease. RegardingmiRNAs in regressing disease,
miR-212, miR-146a, and let-7d were highlighted. Given the
complexity of miRNA-mRNA-transcription factor network,
the understanding of the contribution of network members
and regulatory mechanisms is intricate and requires further
studies which may reveal the functional outcome of the
interactions between the associated molecules.
Our study has several limitations. First, this exploratory
study on miRNA and mRNA expression pattern and their
relationships was performed in unseparated BAL cells. To
obtain complete picture of the regulatory processes ongoing
in sarcoid inflammation, this study should continue by
analysing themiRNA/mRNA expressions in distinct cell sub-
populations. We are also aware that our set of inflammation-
related miRNAs and chemokine/receptor genes, selected
based on their involvement in the pathogenesis of sar-
coidosis, does not cover the whole potential network of
molecules/pathways contributing to this disease. Further, we
did not perform the functional studies needed to confirm the
biological relevance of the obtained relationships between T-
bet, miRNAs, and chemokine network. However, we believe
that our study may contribute to nomination of interesting
relationships for future studies of regulatory mechanisms
involved in the pathogenesis of pulmonary sarcoidosis and
its phenotypes.
5. Conclusions
Our correlation network analysis implies both microR-
NAs and Th1-transcription factor T-bet in the regulation
of cytokine/chemokine-receptor network in BAL cells in
sarcoidosis. Future functional studies are however needed to
confirm the biological relevance of the obtained relationships.
The correlation analysis showed more pronounced regula-
tory capability of T-bet to sarcoidosis-associated chemokine
receptors and cytokines thanmiRNAs, which function rather
as “fine-tuners” of cytokine/chemokine gene expression.
Moreover, we reported altered miRNA pattern in BAL cells
obtained from sarcoidosis patients as well as from subgroups
of patients with progressing and regressing sarcoidosis as
assessed by 2-year follow-up. The knowledge and under-
standing of the regulatorymechanisms underlying the abnor-
mal inflammatory response in sarcoid lungs could shed
light on the cause and progression of sarcoidosis and many
inflammatory and autoimmune diseases.
Abbreviations of Investigated Molecules
CCL2/MCP-1: Chemokine (C-C motif) ligand
2/monocyte chemoattractant protein-1
CCL3/MIP-1A: Chemokine (C-C motif) ligand
3/macrophage inflammatory protein-1
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4/macrophage inflammatory protein-1
beta
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CXCL3/MIP-2B: Chemokine (C-X-C motif) ligand
3/macrophage inflammatory protein-2
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CXCL9/MIG: Chemokine (C-X-C motif) ligand
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10/interferon gamma-induced
protein-10
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CXCL12/SDF-1: Chemokine (C-X-C motif) ligand
12/stromal cell-derived factor-1
CXCL16/SR-
PSOX:
Chemokine (C-X-C motif) ligand
16/scavenger receptor for
phosphatidylserine and oxidized low
density lipoprotein
CCR1: Chemokine (C-C motif) receptor 1
CCR2A: Chemokine (C-C motif) receptor 2,
transcript variant A
CCR2B: Chemokine (C-C motif) receptor 2,
transcript variant B
CCR5: Chemokine (C-C motif) receptor 5
CXCR3: Chemokine (C-X-C motif) receptor 3
CXCR4: Chemokine (C-X-C motif) receptor 4
CXCR6: Chemokine (C-X-C motif) receptor 6
CXCR7: Chemokine (C-X-C motif) receptor 7
IL2: Interleukin 2
IL2RA: Interleukin 2 receptor, alpha
IL2RB: Interleukin 2 receptor, beta
IL15RA: Interleukin 15 receptor, alpha
IFNG: Interferon gamma
PSMB2: Proteasome (prosome, macropain)
subunit, beta type, 2
T-bet: T-box 21, T-cell-specific T-box
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